tc-1

σ1 receptor ligand

STC-15 是一种具有口服活性和有效性的 METTL3 抑制剂，具有抗癌活性，可抑制癌症生长并诱导抗癌免疫。

TC-1827是一种选择性的alpha4beta2激动剂。研究发现，TC-1827能够以钟形剂量依赖方式增加早期LTP。

ETC-159 (ETC-1922159) 是一种具有口服活性的，有效 PORCN 抑制剂。抑制β-catenin 报告基因活性的 IC50值为2.9 nM。

TC-1698 dihydrochloride is a selective nicotinic α7 receptor agonist that also displays weak partial agonist/antagonist activity at β-subunit-containing receptors. This product is a neuroprotectant.

ETC-168是一种选择性的口服有效MNK抑制剂，对MNK1和MNK2的IC50值分别为23 nM和43 nM，在体内和体外均有抗增殖作用。

Sorafenib (Bay 43-9006) 是一种多激酶抑制剂，抑制 Raf-1、B-Raf、VEGFR2、VEGFR3、VEGFR4、PDGFRβ、FLT3、c-Kit 等 (IC50=6/22/90/15/20/20/57/58 nM)，具有口服活性。Sorafenib 具有抗肿瘤活性，可以诱导细胞自噬和凋亡，也可以激动铁死亡。

Ispronicline (TC-1734) 是一种具有口服活性、选择性和有效性的 α4β2 nAChR 部分激动剂，具有抗抑郁、神经保护和持久的认知作用。Ispronicline 对 α4β2 nAChR 具有很高的亲和力，Ki= 11 nM。

Ataluren (PTC124) 是一种可口服的 CFTR-G542X 无义等位基因抑制剂。

Bempedoic acid (ETC1002) 是一种 ATP-柠檬酸裂解酶抑制剂，可激活AMPK。它是脂质和碳水化合物代谢的调节剂。

Complement C1s-IN-1是一种有效的和选择性的补体C1s抑制剂，具有可口服和可穿透脑的优点，以剂量依赖的方式显著抑制人血清诱导的膜攻击复合物的形成，有效阻断经典补体途径

TC14012 acetate 是 T140 的血清稳定衍生物，是一种选择性的肽模拟 CXCR4 拮抗剂，IC50 为 19.3 nM。 TC14012 还是一种有效的 CXCR7 激动剂，EC50 为 350 nM，可将 β-arrestin 2 募集到 CXCR7。 TC14012 具有抗癌活性和抗 HIV 活性。

TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) 是一种有效的肿瘤细胞增殖抑制剂，并通过激活 caspase-3、8 和 9 诱导细胞凋亡。在长时间有丝分裂阻滞期间，它诱导 MCL1降解导致凋亡。它作为苯酞酰亚胺衍生物在结构上与免疫调节药物相关。

AAL Toxin TC1 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T125567。

SPR206 is a polymyxin analogue and an important class of antibiotic for the treatment of bacterial infections due to multidrug resistant Gram-negative pathogen.

TMP778 is an effective and selective RORγt inverse agonist (IC50: 7 nM in FRET assay).

TC13172是一种靶向混合谱系激酶结构域样蛋白（MLKL）的强效共价抑制剂，在10 µM浓度下对MLKL表现出显著选择性，优于密切相关的受体相互作用丝氨酸/苏氨酸激酶1（RIPK1）和RIPK3。TC13172能以2 nM的EC50有效抑制TSZ组合（TNF-α、Smac模拟物和Z-VAD-FMK）诱导的HT-29细胞坏死性凋亡，并在100 nM浓度下阻断TSZ诱导的MLKL寡聚化和质膜转位。

(S)-dHTC1 是一种分子胶降解剂，主要作用于转录共激活因子ENL。此化合物在与ENL形成复合物后，能够以高亲和力结合连接酶，其IC50为93 nM。在MV4;11细胞中，(S)-dHTC1 降解ENL的DC50为26 nM。此化合物可用于急性髓系白血病的研究。

nicotinic α7 receptor agonist

Ezutromid (BMN 195) 是一种具有口服活性的、首创的苯并恶唑 utrophin 调节剂，EC50=0.91 μM。它抑制人肝微粒体 CYP1A2 酶活性，IC50=5.4 μM。它可用于 Duchenne 型肌营养不良症 (DMD) 的研究。

RTC13 是一种通读试剂，可在杜氏肌营养不良症 （DMD） 的 mdx 小鼠模型中恢复抗肌萎缩蛋白表达的能力。

RTC14, as a premature termination codon (PTC) readthrough inducer, can act by restoring dystrophin expression and improving muscle function in the mdx mouse model for Duchenne muscular dystrophy.

STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.1 It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o'nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR).References1. Gall, B., Pryke, K., Abraham, J., et al. Emerging alphaviruses are sensitive to cellular states induced by a novel small-molecule agonist of the STING pathway. J. Virol. 92(6), e01913-01917 (2018). STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.1 It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o'nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR). References1. Gall, B., Pryke, K., Abraham, J., et al. Emerging alphaviruses are sensitive to cellular states induced by a novel small-molecule agonist of the STING pathway. J. Virol. 92(6), e01913-01917 (2018).

SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate effectively combats bacterial infections. Notably, SPR206 acetate demonstrates significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301.